New Leaf Ventures Past Earnings Performance
Past criteria checks 0/6
New Leaf Ventures's earnings have been declining at an average annual rate of -20.3%, while the Pharmaceuticals industry saw earnings growing at 67.6% annually. Revenues have been growing at an average rate of 30.7% per year.
Key information
-20.3%
Earnings growth rate
29.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 30.7% |
| Return on equity | n/a |
| Net Margin | -430.1% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Revenue & Expenses Breakdown
How New Leaf Ventures makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1 | -6 | 4 | 0 |
| 30 Jun 23 | 2 | -6 | 4 | 0 |
| 31 Mar 23 | 2 | -5 | 4 | 0 |
| 31 Dec 22 | 2 | -4 | 3 | 0 |
| 30 Sep 22 | 2 | 0 | 2 | 0 |
| 30 Jun 22 | 2 | -1 | 3 | 0 |
| 31 Mar 22 | 2 | -2 | 4 | 0 |
| 31 Dec 21 | 2 | -4 | 5 | 0 |
| 30 Sep 21 | 3 | -8 | 4 | 0 |
| 30 Jun 21 | 3 | -7 | 4 | 0 |
| 31 Mar 21 | 3 | -8 | 3 | 0 |
| 31 Dec 20 | 2 | -7 | 2 | 0 |
| 30 Sep 20 | 1 | -3 | 2 | 0 |
| 30 Jun 20 | 1 | -3 | 2 | 0 |
| 31 Mar 20 | 0 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
| 30 Sep 19 | 0 | -1 | 1 | 0 |
Quality Earnings: NLV is currently unprofitable.
Growing Profit Margin: NLV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NLV is unprofitable, and losses have increased over the past 5 years at a rate of 20.3% per year.
Accelerating Growth: Unable to compare NLV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NLV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (39.8%).
Return on Equity
High ROE: NLV's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.